An evaluation of sPLA2 as a therapeutic target is timely to help put into context the recent announcement that a phase III randomized trial (VISTA-16 [Vascular Inflammation Suppression to Treat Acute Coronary Syndrome for 16 Weeks] trial) (10) of varespladib, a first-in-class sPLA2 inhibitor (9) for major vascular event (MVE) prevention in patients with acute coronary syndrome (ACS), was stopped prematurely for lack of efficacy (11). Here, PLA2G2A is linked to acute coronary syndrome.